Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.

Sadeleştirilmiş öğe sayfası
dc.contributor.authorPilanci, Kezban Nur
dc.contributor.authorSaglam, Sezer
dc.contributor.authorOkyar, Alper
dc.contributor.authorYucel, Serap
dc.contributor.authorKara, Zeliha Pala
dc.contributor.authorOrdu, Cetin
dc.contributor.authorNamal, Esat
dc.contributor.authorCiftci, Rumeysa
dc.contributor.authorKoksal, Ulkuhan
dc.contributor.authorSaglam, Esra Kaytan
dc.date.accessioned2025-10-16T15:31:07Z
dc.date.issued2015
dc.description.abstractAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Chicago, IL, MAY 29-JUN 02, 2015
dc.identifier.doi10.1200/jco.2015.33.15\_suppl.e14646
dc.identifier.otherWOS:000358036902740
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/8986
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleChronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS